ReviewJapanese journal of radiology2026
Multimodal MRI insights into hippocampal pathological changes across the Alzheimer's disease continuum: advances and challenges.
Review in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, with early and progressive hippocampal pathology serving as a hallmark across the AD continuum, including subjective cognitive decline, mild cognitive impairment, and AD dementia. Single-modal MRI fails to fully capture multilevel hippocampal neuropathology, hindering accurate early diagnosis and prognostic prediction of AD. This narrative review summarizes recent advances in structural MRI, diffusion tensor imaging, magnetic resonance spectroscopy, quantitative susceptibility mapping, arterial spin labeling, and functional MRI for evaluating hippocampal and medial temporal lobe abnormalities in AD. These techniques provide a multifaceted characterization of AD-associated hippocampal alterations, including macroscopic atrophy, microstructural degeneration, metabolic dysregulation, aberrant iron deposition, hemodynamic dysfunction, and abnormal neuronal activity. Hippocampal damage in AD exhibits distinct subfield specificity, hemispheric asymmetry, and stage-dependent progression, modulated by Aβ/tau pathology, neuroinflammation, and apolipoprotein E ε4 genotype. Notably, multimodal imaging fusion integrated with machine learning outperforms single-modal biomarkers, significantly improving the accuracy of AD early screening, differential diagnosis, and prognostic prediction. Nevertheless, existing studies are hampered by inadequate pathological validation, limited sample sizes, unsatisfactory reproducibility, and multicenter technical heterogeneity. Multimodal MRI offers robust non-invasive evidence for exploring AD hippocampal pathophysiology. Future large-scale multicenter longitudinal studies combining artificial intelligence will advance precision diagnosis and targeted therapy for AD by clarifying the interplay among AD pathology, genetics, and heterogeneous hippocampal injury.
Indexed as
Identifiers
42599667What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.